Arrowhead Pharmaceuticals, Inc.

NasdaqGS:ARWR Stock Report

Market Cap: US$2.7b

Arrowhead Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Arrowhead Pharmaceuticals's earnings have been declining at an average annual rate of -53.8%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 6% per year.

Key information

-53.8%

Earnings growth rate

-52.4%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate6.0%
Return on equity-161.5%
Net Margin-2,741.4%
Next Earnings Update26 Nov 2024

Recent past performance updates

Recent updates

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Oct 04
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

Arrowhead Pharmaceutical: Driving To Commercialization

Jul 26

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jun 12
Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: Hoping Something Sticks

May 27

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

May 21
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

May 17

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03
Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08
Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19
Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25
Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19
Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17
Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10
Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24
A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24
We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Arrowhead Pharma: We Can Afford To Wait For More Proof

Jun 28

Revenue & Expenses Breakdown

How Arrowhead Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:ARWR Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2420-539121446
31 Mar 2435-471119390
31 Dec 23182-297113368
30 Sep 23241-205109337
30 Jun 23256-181117320
31 Mar 23273-150125298
31 Dec 22278-155135301
30 Sep 22243-176137284
30 Jun 22250-154141269
31 Mar 22263-112123258
31 Dec 21144-183104228
30 Sep 21138-14185202
30 Jun 21108-12664178
31 Mar 2189-11056151
31 Dec 2080-10355137
30 Sep 2088-8554127
30 Jun 20124-2452105
31 Mar 20139104691
31 Dec 19164533584
30 Sep 19169682781
30 Jun 19137462572
31 Mar 1995102366
31 Dec 1847-292058
30 Sep 1816-541953
30 Jun 1814-541851
31 Mar 1822-441651
31 Dec 1731-351354
30 Sep 1731-342049
30 Jun 1723-462549
31 Mar 1713-603246
31 Dec 164-754240
30 Sep 160-822561
30 Jun 160-844139
31 Mar 160-814037
31 Dec 150-893639
30 Sep 150-923547
30 Jun 150-903245
31 Mar 150-853044
31 Dec 140-712837
30 Sep 140-592523
30 Jun 140-501917
31 Mar 140-441613
31 Dec 130-371310

Quality Earnings: ARWR is currently unprofitable.

Growing Profit Margin: ARWR is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ARWR is unprofitable, and losses have increased over the past 5 years at a rate of 53.8% per year.

Accelerating Growth: Unable to compare ARWR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ARWR is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: ARWR has a negative Return on Equity (-161.48%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies